Oral vaccination with Salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague

被引:61
作者
Yang, Xinghong
Hinnebusch, B. Joseph
Trunkle, Theresa
Bosio, Catharine M.
Suo, Zhiyong
Tighe, Mike
Harmsen, Ann
Becker, Todd
Crist, Kathryn
Walters, Nancy
Avci, Recep
Pascual, David W.
机构
[1] Montana State Univ, Bozeman, MT 59717 USA
[2] NIAID, Lab Zoonot Pathogens, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA
[3] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80521 USA
[4] Montana State Univ, Dept Phys, Bozeman, MT 59717 USA
关键词
D O I
10.4049/jimmunol.178.2.1059
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The gut provides a large area for immunization enabling the development of mucosal and systemic Ab responses. To test whether the protective Ags to Yersinia pestis can be orally delivered, the Y. pestis caf1 operon, encoding the F1-Ag and virulence Ag (V-Ag) were cloned into attenuated Salmonella vaccine vectors. F1-Ag expression was controlled under a promoter from the caf1 operon; two different promoters (P), PtetA in pV3, PphoP in pV4, as well as a chimera of the two in pV55 were tested. F1-Ag was amply expressed; the chimera in the pV55 showed the best V-Ag expression. Oral immunization with Salmonella-F1 elicited elevated secretory (S)-IgA and serum IgG titers, and Salmonella-V-Ag(pV55) elicited much greater S-IgA and serum IgG Ab titers than Salmonella-V-Ag(pV3) or Salmonella-V-Ag(pV4). Hence, a new Salmonella vaccine, Salmonella-(F1+V)Ags, made with a single plasmid containing the caf1 operon and the chimeric promoter for V-Ag allowed the simultaneous expression of F1 capsule and V-Ag. Salmonella-(F1+V)Ags elicited elevated Ab titers similar to their monotypic derivatives. For bubonic plague, mice dosed with Salmonella-(F1+V)Ags and Salmonella-Fl-Ag showed similar efficacy (> 83% survival) against similar to 1000 LD50 Y. pestis. For pneumonic plague, immunized mice required immunity to both F1- and V-Ags because the mice vaccinated with Salmonella-(F1+V)Ags protected against 100 LD50 Y. pestis. These results show that a single Salmonella vaccine can deliver both F1- and V-Ags to effect both systemic and mucosal immune protection against Y. pestis.
引用
收藏
页码:1059 / 1067
页数:9
相关论文
共 57 条
  • [1] Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice
    Anderson, GW
    Heath, DG
    Bolt, CR
    Welkos, SL
    Friedlander, AM
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1998, 58 (06) : 793 - 799
  • [2] Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis
    Anderson, GW
    Leary, SEC
    Williamson, ED
    Titball, RW
    Welkos, SL
    Worsham, PL
    Friedlander, AM
    [J]. INFECTION AND IMMUNITY, 1996, 64 (11) : 4580 - 4585
  • [3] Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis
    Andrews, GP
    Strachan, ST
    Benner, GE
    Sample, AK
    Anderson, GW
    Adamovicz, JJ
    Welkos, SL
    Pullen, JK
    Friedlander, AM
    [J]. INFECTION AND IMMUNITY, 1999, 67 (03) : 1533 - 1537
  • [4] Anisimov A. P., 2002, Molekulyarnaya Genetika Mikrobiologiya i Virusologiya, P3
  • [5] Ascón MA, 1998, INFECT IMMUN, V66, P5470
  • [6] TOWARDS A LIVE ORAL VACCINE AGAINST ENTERO-TOXIGENIC ESCHERICHIA-COLI OF SWINE
    ATTRIDGE, S
    HACKETT, J
    MORONA, R
    WHYTE, P
    [J]. VACCINE, 1988, 6 (05) : 387 - 389
  • [7] Oral delivery of foreign antigens by attenuated Salmonella: Consequences of prior exposure to the vector strain
    Attridge, SR
    Davies, R
    LaBrooy, JT
    [J]. VACCINE, 1997, 15 (02) : 155 - 162
  • [8] BARTELLO.PJ, 1973, MIL MED, V138, P720
  • [9] Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters
    Bullifent, HL
    Griffin, KF
    Jones, SM
    Yates, A
    Harrington, L
    Titball, RW
    [J]. VACCINE, 2000, 18 (24) : 2668 - 2676
  • [10] CAVANAUGH DC, 1959, J IMMUNOL, V83, P348